Navigation Links
ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Interleukin Genetics, Inc. (AMEX:ILI) and collaborators at the University of California San Diego today reported at the American College of Cardiology annual meeting that associations between coronary artery disease (CAD) and both oxidized phospholipids (OxPL) and Lp(a) levels appear to be dependent on pro-inflammatory variants of the interleukin-1 (IL-1) genes.

In a presentation titled "The Influence of Oxidized Phospholipids and Lp(a) Lipoprotein on Coronary Artery Disease Is Conditional Upon Genotype at the Interleukin-1 Region," the investigators reported that in patients with the pro-inflammatory IL-1 genotypes, higher levels of OxPL or Lp(a) were associated with significantly increased risk for CAD (P less than 0.01). This effect was strongly accentuated in patients less than 60 years old (P=0.0001). In contrast, patients who did not express, the pro-inflammatory IL-1 genotypes demonstrated no association between OxPL levels and CAD. These findings were found to be independent of other standard risk factors, including C-reactive protein.

"Oxidized phospholipids play a critical role in the initiation and progression of cardiovascular disease. These new data suggest a novel and clinically relevant biological link between pro-inflammatory IL-1 genotypes, oxidation of phospholipids and predisposition to CAD in younger individuals," said Sotirios Tsimikas, M.D., Associate Professor of Clinical Medicine and Director of Vascular Medicine, University of California San Diego.

The study was conducted under the direction of Drs. Joseph Witztum and Sotirios Tsimikas from the Divisions of Endocrinology and Metabolism and Cardiovascular Diseases, University of California San Diego and involved collaborators from Interleukin Genetics, the University of Sheffield, England and the Geisinger Center for Health Research.

About Interleukin Genetics

In terleukin Genetics, Inc. is focused on developing, acquiring, and commercializing personalized health products that can help individuals improve and maintain their health through preventive measures. It uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. The Company also develops and markets nutritional and OTCeutical(R) products. Interleukin has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. In addition, through its Alan James Group subsidiary which it acquired in August 2006, Interleukin sells its nutritional product brands, including Ginkoba(R), Ginsana(R), and Venastat(R) through the nation's largest food, drug and mass retailers. The Company's current development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as its new proprietary OTCeuticals for distribution through Alan James Group. The Company expects that these programs will also lead to the personalized selection of nutritional products, and provide consumers and healthcare professionals with better preventive product alternatives. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to make progress in advancing our core technologies, and our expectations regarding fiscal year 2006 revenues and gross profit margins of our nutritional supplement products. Because such statements include risks and uncertainties, actual results may diff er materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

Contact

For Interleukin Genetics:
Paul Voegelin, 781-398-0700


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
(Date:2/12/2016)... 2016  Innophos Holdings, Inc. (NASDAQ: IPHS ), a ... announced that it will host a live conference call on ... its fourth quarter and full year 2015 results. ... detailing fourth quarter and full year results will be issued ... --> --> The conference call ...
(Date:2/12/2016)... Mass. , Feb. 12, 2016   HeartWare ... a conference call and webcast to discuss its financial ... 31, 2015, on Thursday, February 25, 2016 at 8:00 ... results prior to the conference call and webcast.  On ... company,s financial results, highlights from the fourth quarter and ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Valentine’s Day ... a date for the big day. A great outfit, flawless hair, and a sparkling ... might as well resign themselves to a night at home with Rover. (Actually, man’s ...
(Date:2/13/2016)... ... 13, 2016 , ... Many individuals looking to lead a healthy lifestyle have ... IsoPasta by Isolator Fitness has delved into this niche allowing those giving up ... repercussions. IsoPasta has 30 grams of protein and only 7 grams of carbohydrates ...
(Date:2/13/2016)... ... 13, 2016 , ... The producers of Enterprises TV are pleased ... increasingly modern world of instantaneous consumption proves very convenient for businesses. With new technologies ... and coal, which pollutes our air, water, and soil. It can also threaten the ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/13/2016)... ... ... In the early or “honeymoon” stage of a relationship, couples strive to put ... to be romantic, and may exaggerate a strength or two in an effort to ... , A recent study from Queendom.com , however, suggests that new couples who ...
Breaking Medicine News(10 mins):